CD274 and extranodal nasal NK/T cell lymphoma: The anti-PD-L1 monoclonal antibody avelumab, when used as monotherapy, showed an ORR of 38% and a CR of 24% in a phase 2 trial that included 21 patients with r/r NKTCL (106).